Objective：To observe the clinical characteristics of hepatocellular carcinoma(HCC)in Shenzhen and the effect of Qishu Kangai prescription in Chinese medicine combined with transcatheter arterial chemoe mbolization(TACE)therapy on the survival time and quality of life of patients.Methods：Retrospectively investigated 260 cases of patients with HCC who were in outpatients and inpatients of liver diseases in Shenzhen Traditional Chinese Medicine Hospital，analyzed their sex，age of onset and etiology.Evaluated quality of life(KPS)of 260 cases of patients with HCC and made a survival analysis，in which 63 cases(the experiment group)were given Qishu Kangai prescription in Chinese medicine combined with TACE for treatment，34 cases(the control group)were given TACE therapy for treatment，and 14 cases(the Chinese medicine group)were given Qishu Kangai prescription for treatment，and evaluated the clinical effect.Results：The incidence rate of HCC in males and females in Shenzhen was 4.5∶ 1，among the age of 40-60.The major causes of HCC were hepatitis B virus(HBV)infection and liver cirrhosis.There was a significant difference being found in the comparison of KPS scores in the experiment group and the control group(P ＜ 0.05).Kaplan-Meier analysis found that，compared with the control group，there was a statistically significant difference in the survival rate between the experiment group and the Chinese medicine group(P<0.05)，being higher than that of the controlgroup.The survival rate of over 60-years-old patients in the Chinesemedicine group was higher than that in the experiment group，difference being significant(P ＜ 0.05).Conclusions：In Shenzhen，HCC occurs frequently in men between the ages of 40 and 60 with HBV infection or cirrhosis.Some elderly patients with HCC who receive appropriate Chinese medicine treatment but without surgery may also improve the survival rate and quality of life.The therapy of Qishu Kangai prescription in Chinese medicine combined with TACE can improve the quality of life and survival time of patients with HCC atmiddle stage.